Monica Cespedes Santana, MD
Infectious Disease · San Juan, PRNPI 1114204161
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $1,924 of the $2,212 with a category attached, or 87.0%. 15 manufacturers reported payments, led by Johnson & Johnson at 26.2% of the total. Reporting peaked in 2021 at $726 and has fallen 83.8% since, to $118 in 2024.
Across 82 payments — averaging $26.98 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Johnson & Johnson$580
- Janssen Products, LP$409
- Viiv Healthcare Company$333
- Gilead$179
- AbbVie$143
- Insmed, Inc.$125
- plus $443 from 9 others
What the payments were for
- Food & beverage$1,92487%
- Education$28813%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Johnson & Johnson | 28 | $580 |
| Janssen Products, LP | 4 | $409 |
| Viiv Healthcare Company | 17 | $333 |
| Gilead | 9 | $179 |
| AbbVie | 7 | $143 |
| Insmed, Inc. | 1 | $125 |
| E.r. Squibb & Sons, L.L.C. | 1 | $118 |
| Theratechnologies Inc. | 1 | $92 |
| Vanda Pharmaceuticals Inc. | 3 | $58 |
| Merck | 3 | $53 |
| Paratek Pharmaceuticals, Inc. | 3 | $49 |
| Melinta Therapeutics, LLC | 2 | $24 |
| Daiichi Sankyo Inc. | 1 | $23 |
| Astellas Pharma US Inc | 1 | $20 |
| Abbott | 1 | $8 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$2,212 in reported general payments places this provider in the 70th percentile of 127 infectious disease providers in Puerto Rico.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Fosfomycin Tromethamine | 11 | $2,157 |
| Doxycycline Hyclate | 22 | $615 |
| Ciprofloxacin Hcl | 33 | $303 |
| Cephalexin | 15 | $165 |
Paid to pharmacies, not to this prescriber.
Other infectious disease in San Juan
- Vanessa Olivo EchavarrySan Juan$41K
- Angeles Rodriguez RosaSan Juan$27K
- Miguel Colon PerezSan Juan$12K
- Javier MoralesSan Juan$9K
- Mario LopezSan Juan$9K
- Armando Torres NievesSan Juan$4K
- Carmelo Santana-LopezSan Juan$4K
- Elba Arroyo CamunasSan Juan$3K
- Jonathan Ruiz GarciaSan Juan$3K
- Sandra Maldonado-RiveraSan Juan$3K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.